Cardiomyopathies
Conditions
Interventions
Mitoxantrone Group:NA
Alkylating agents and antimetabolizers Group:NA
Control Group:NA
Sponsors
Huadong Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 60 Years
Inclusion criteria
Inclusion criteria: 1. patients with hematological malignancies undergoing autologous or allogeneic hematopoietic stem cell transplantation; 2. Patients with hematological malignancies receiving conventional chemotherapy; 3. aged 18-60 years old; 4. Liver and renal function: serum bilirubin <=35µmol/L, AST/ALT < 2 times of the upper limit of normal, blood muscle liver <=150µmol/L; 5. normal cardiac function; 6. physical status score 0-2 (ECOG score); 7. Informed consent was obtained from patients or their family members;
Exclusion criteria
Exclusion criteria: 1. obvious contraindications to chemotherapy drugs; 2. abnormal liver and kidney function beyond the inclusion criteria; 3. severe heart disease, including myocardial infarction and cardiac insufficiency; 4. concurrent malignant tumors of other organs; 5. active TB patients and HIV positive patients; 6. patients with other hematological diseases; 7. pregnant or lactating women; 8. cannot understand or adhere to the study protocol; 9. previous history of intolerance or allergy to drugs in the same class; 10. Co-participating with other clinical investigators; 11. any other circumstances that may prevent the conduct of the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| myocardial enzyme;brain natriuretic peptide, BNP;Endocardial longitudinal strain;Circumferential strain of endocardium;Endocardial strain;cardiac efficiency; | — |
Secondary
| Measure | Time frame |
|---|---|
| Incidence of Heart Failure;Overall survival;safety; | — |
Countries
China
Contacts
Public ContactLynn
Huadong Hospital
Outcome results
None listed